Drug industry sets lobbying records as pricing pressure looms
The drug industry set several quarterly records for lobbying spending in the first three months of 2018, but Indianapolis-based Eli Lilly and Co. actually reduced lobbying expenditures.
Pharmaceutical
Articles
Americans filling far fewer opioid prescriptions, new report says
The number of prescriptions for opioid painkillers filled in the United States fell dramatically last year, showing their biggest drop in 25 years.
Indiana group to create app to teach doctors about opioids
The Richard M. Fairbanks Foundation awarded $230,000 to the Indiana State Medical Association this week to develop the app and an accompanying podcast.
Lilly signs licensing deal with biotech startup for diabetes drug
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
High court asked to take case that could determine size of eye drops
What most people see as an annoyance, some prescription drop users say is grounds for a lawsuit.
Former Lilly CFO Rice to lead CVS Caremark, report says
Derica Rice, 53, one of the nation’s most powerful black executives, retired from Indianapolis-based drugmaker Eli Lilly and Co. in December, after the company passed him over when naming a new CEO.
House rejects GOP bill easing use of unproven drugs
The House rejected legislation Tuesday that would ease how experimental drugs are provided to people with terminal illnesses.
‘Rigged’ system blocks lower-cost drugs, head of FDA says
FDA Commissioner Scott Gottlieb aimed particular criticism at giant pharmacy benefit managers that contract with health plans to administer coverage of drugs, saying the industry’s tactics have stymied cheaper copies of expensive biotechnology drugs.
FDA opens new path for Alzheimer’s therapy as failures mount
The Food and Drug Administration proposal will create new opportunities for drugmakers after repeated failures from companies including Indianapolis-based Eli Lilly and Co.
Hot-selling Lilly anti-inflammatory drug passes key hurdle for third use
The Indianapolis-based drugmaker said the medicine, called Taltz, proved effective for treating a type of back stiffness, and hopes to submit it for government approval this year.
Report: Opioid makers gave $10M to advocacy groups amid epidemic
Companies selling some of the most lucrative prescription painkillers funneled millions of dollars to advocacy groups that in turn promoted the medications' use, according to a report released Monday
Trump’s big promises on drug costs followed by modest steps
As a candidate, President Trump advocated Medicare negotiations and allowing consumers to import medicines from abroad. His current strategy recommends changes to policies that the administration believes unwittingly lead to higher prices, and suggests ways to speed drugs to market and increase competition.
Secret discounts keep drug bills from soaring, middlemen say
Express Scripts Holding Co., one of the biggest pharmacy-benefits managers, says the drug-price deals it cuts behind closed doors are saving consumers a lot of money.
Hospital groups creating company to make cheap generic drugs
Several major not-for-profit hospital groups, including the parent of St. Vincent Health in Indianapolis, are trying their own solution to drug shortages and high prices.
Lilly looks to boost pipeline with drug partnerships
A slimmed-down Eli Lilly and Co., thousands of employees lighter after its biggest restructuring in nearly a decade, is now looking high and low for deals to bulk up its drug pipeline.
Trump health pick wary of government drug price negotiations
Alex Azar, a former Eli Lilly and Co. executive, acknowledged to the Senate Finance Committee that drug prices are too high and said he'd work to lower them if confirmed as secretary of Health and Human Services.
Nearly a dozen Indiana communities sue opioid industry in new flurry of suits
A wide array of cities, towns and counties are blaming opioid makers and distributors for flooding their communities with addictive painkillers.
Pfizer to end Alzheimer’s research, cut 300 jobs
Pfizer said it will continue its support of potential blockbuster drug tanezumab, a late-stage pain treatment in development with Indianapolis-based Eli Lilly and Co.
Assembly Biosciences’ market value surges to nearly $1B, despite red ink
The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.
Is marijuana debate at a tipping point?
A fight over whether Indiana should legalize medical marijuana seems all but inevitable now.